Last reviewed · How we verify
placebo to levocetirizine
placebo to levocetirizine is a H1-receptor antagonist (second-generation antihistamine) Small molecule drug developed by Brian J Lipworth. It is currently FDA-approved for Allergic rhinitis, Chronic urticaria, Allergic conjunctivitis.
Levocetirizine is a selective H1-receptor antagonist that blocks histamine signaling to reduce allergic symptoms.
Levocetirizine is a selective H1-receptor antagonist that blocks histamine signaling to reduce allergic symptoms. Used for Allergic rhinitis, Chronic urticaria, Allergic conjunctivitis.
At a glance
| Generic name | placebo to levocetirizine |
|---|---|
| Sponsor | Brian J Lipworth |
| Drug class | H1-receptor antagonist (second-generation antihistamine) |
| Target | H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Allergy/Immunology |
| Phase | FDA-approved |
Mechanism of action
Levocetirizine is the active enantiomer of cetirizine, a second-generation antihistamine that selectively antagonizes peripheral H1 receptors without significant central nervous system penetration. By blocking histamine binding at H1 receptors on mast cells and basophils, it prevents the cascade of allergic responses including itching, urticaria, and rhinitis symptoms. This study appears to be a placebo-controlled trial comparing levocetirizine efficacy.
Approved indications
- Allergic rhinitis
- Chronic urticaria
- Allergic conjunctivitis
Common side effects
- Somnolence
- Headache
- Fatigue
- Dry mouth
Key clinical trials
- Parallel, Double-dummy, Superiority Study Levocetirizine/Pseudoephedrine x Zina for Allergic Rhinitis in Brazil (PHASE3)
- COrticosteroids in acUte uRticAria in emerGency dEpartment (PHASE3)
- A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3) (PHASE3)
- The Duration of the Suppressive Effects of Desloratadine on Allergen Prick Tests After Discontinuation (P04441) (PHASE4)
- Characterization of the Role of Histamine in Children With Asthma (PHASE2, PHASE3)
- A Trial to Evaluate the Effect of Vitamin D Supplementation in Patients With Chronic Urticaria (PHASE4)
- To Evaluate Adenosine Monophosphate and Allergen Challenge in Allergic Rhinitis (PHASE4)
- Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- placebo to levocetirizine CI brief — competitive landscape report
- placebo to levocetirizine updates RSS · CI watch RSS
- Brian J Lipworth portfolio CI
Frequently asked questions about placebo to levocetirizine
What is placebo to levocetirizine?
How does placebo to levocetirizine work?
What is placebo to levocetirizine used for?
Who makes placebo to levocetirizine?
What drug class is placebo to levocetirizine in?
What development phase is placebo to levocetirizine in?
What are the side effects of placebo to levocetirizine?
What does placebo to levocetirizine target?
Related
- Drug class: All H1-receptor antagonist (second-generation antihistamine) drugs
- Target: All drugs targeting H1 receptor
- Manufacturer: Brian J Lipworth — full pipeline
- Therapeutic area: All drugs in Allergy/Immunology
- Indication: Drugs for Allergic rhinitis
- Indication: Drugs for Chronic urticaria
- Indication: Drugs for Allergic conjunctivitis
- Compare: placebo to levocetirizine vs similar drugs
- Pricing: placebo to levocetirizine cost, discount & access